Treatment of erythrodermic psoriasis with biologics: A systematic review - 08/05/20
, Gabriela Pabón-Cartagena, MD b, Leyre A. Falto-Aizpurua, MD a, Marely Santiago-Vázquez, MD a, Karina J. Cancel-Artau, BS c, Gabriel Arias-Berrios, MD a, Rafael F. Martín-García, MD aCet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Background |
Biologic medications for plaque psoriasis have been used to treat erythrodermic psoriasis (EP). Since the guidelines for management of EP were published, new biologic medications have been approved for the treatment of plaque psoriasis.
Objective |
To analyze the evidence of biologic medications in the treatment of EP based on response and tolerability.
Methods |
A comprehensive search was conducted with the PubMed, Cochrane Library, Embase, and Scopus databases through December 31, 2018. Studies reporting 1 or more cases of EP, defined as >75% body surface area involvement, in patients aged ≥18 years treated with biologics were included. Baseline Psoriasis Area and Severity Index score, score improvement, and adverse events were documented. Adequate response to treatment was defined as Psoriasis Area and Severity Index ≥50.
Results |
Included were 43 articles, yielding a total of 179 patients. Most patients responded at some point during treatment, with a higher level of evidence for infliximab, ustekinumab, ixekizumab, and guselkumab. Infection was the most common adverse event (n = 35).
Limitations |
Data are limited to case reports, case series, and uncontrolled studies.
Conclusion |
Patients with EP treated with biologics demonstrated positive responses and treatment was well-tolerated, with a weak recommendation and limited quality of evidence in favor of infliximab, ustekinumab, ixekizumab, and guselkumab.
Le texte complet de cet article est disponible en PDF.Key words : adalimumab, biologics, erythrodermic psoriasis, etanercept, golimumab, guselkumab, infliximab, ixekizumab, psoriasis, secukinumab, ustekinumab
Abbreviations used : AE, EP, PASI
Plan
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not necessary for this systematic review due to all the data being taken from public, anonymous literature. |
|
| Reprints are not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?